The Efficacy of Brimonidine in Decreasing Elevations in Intraocular Pressure after Laser Trabeculoplasty

Howard S. Barnebey, Alan L. Robin, Thom J. Zimmerman, John C. Morrison, Stanley B. Hersh, Richard A. Lewis, Anne L. Coleman, Donald J. Cinotti, John Walt, Kuankuan S. Chen, Elaine P. Kelley

Research output: Contribution to journalArticlepeer-review

54 Scopus citations


Purpose: The authors explored the empirical dosing requirement for administration of an a2-adrenoceptor agonist, brimonidine, and determined its efficacy in decreasing elevations in intraocular pressure (IOP) after 360° argon laser trabeculoplasty (ALT). Methods: This vehicle-controlled, double-masked, multicenter trial evaluated three dosing regimens of brimonidine. Two hundred thirty-two patients for whom 360° ALT was indicated were randomized into one of four treatment groups: 0.5% brimonidine both before and after ALT; brimonidine before but vehicle after ALT; vehicle before but brimonidine after ALT; or vehicle at both times. Results: During the first 3 hours after 360° ALT, the overall incidence of IOP elevations of 5 mmHg or greater was 38% (23 of 60 eyes) in the group receiving vehicle only, and it ranged from 3% to 9% (2 of 62 to 5 of 53 eyes) in the groups receiving any brimonidine treatment. There was little difference in efficacy between the three dosing regimens of brimonidine. Brimonidine was well tolerated by the patients. Conclusion: Based on this large, controlled, multicenter study, 0.5% brimonidine was an effective agent for reducing elevations in IOP after 360° ALT. Only one dose, administered either before or after 360° ALT, was required.

Original languageEnglish (US)
Pages (from-to)1083-1088
Number of pages6
Issue number7
StatePublished - 1993

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'The Efficacy of Brimonidine in Decreasing Elevations in Intraocular Pressure after Laser Trabeculoplasty'. Together they form a unique fingerprint.

Cite this